Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participants - Individual Prediction and Prevention of Risks of Immunosuppressive Therapies in Transplantation Access content directly
Journal Articles Journal of Hepatology Year : 2018

Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participants

G. Hanna
  • Function : Author
P. Hwang
  • Function : Author
F. Dutko
  • Function : Author
A. Guidoum
  • Function : Author
K. Hagen
  • Function : Author
B. Haber
  • Function : Author
No file

Dates and versions

hal-03590864 , version 1 (28-02-2022)

Identifiers

Cite

T. Asselah, S. Pol, C. Hezode, V. Loustaud-Ratti, V. Leroy, et al.. Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participants. Journal of Hepatology, 2018, 68 (1), pp.S3-S4. ⟨10.1016/S0168-8278(18)30225-3⟩. ⟨hal-03590864⟩
29 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More